Uretron D/S .12 mg/1
Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate · TABLET · DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals
Uretron D/S is a prescription tablet containing methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate at .12 mg/1, taken oral. Manufactured by DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals.
Key Facts
- Brand Name
- Uretron D/S
- Generic Name
- Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate
- NDC Code (Product)
12539-144- Manufacturer
- DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals
- Strength
- .12 mg/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- HUMAN PRESCRIPTION DRUG
- Drug Class
- Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
- Marketing Start
- 10/07/2022
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE Uretron D/S tablets are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.
Dosage & Administration
DOSAGE AND ADMINISTRATION Adults - O ne tablet orally 4 times per day followed by liberal fluid intake. Older Children - Dosage must be individualized by physician. Not recommended for use in children six years of age or younger.
Warnings
WARNINGS Do not exceed recommended dosage. If rapid pulse, dizziness or blurring of vision occurs discontinue use immediately.
Contraindications
CONTRAINDICATIONS Hypersensitivity to any of the ingredients is possible. Risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).
Drug Interactions
Drug interactions As a result of hyoscyamine's effects on gastrointestinal motility and gastric emptying, absorption of other oral medications may be decreased during concurrent use with this combination medication. Methylene blue inhibits a range of CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5. This interaction could be more pronounced with narrow therapeutic index drugs that are metabolized by one of these enzymes (e.g., digoxin, warfarin, phenytoin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus). However, the clinical relevance of these in vitro interactions is unknown. Urinary alkalizers and thiazide diuretics: May cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde. Antimuscarinics : Concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications. Antacids/antidiarrheals: Concurrent use may reduce absorption of hyoscyamine resulting in decreased therapeutic effectiveness. Concurrent use with antacids may cause urine to become alkaline reducing t…
Adverse Reactions
ADVERSE REACTIONS Cardiovascular: rapid heartbeat, flushing Central Nervous System: blurred vision, dizziness, drowsiness Genitourinary: difficult micturition, acute urinary retention Gastrointestinal: dry mouth, nausea and vomiting Respiratory: shortness of breath or trouble breathing Serious allergic reactions to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious allergic reaction, including itching, rash, severe dizziness, swelling or trouble breathing. This medication can cause urine and sometimes stools to turn blue to blue-green. This effect is harmless and will subside after medication is stopped. Call your doctor or physician for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact A.G. Marin Pharmaceuticals at 305-593-5333 or FDA at 1-800-FDA-1088, www.fda.gov/medwatch. Drug interactions As a result of hyoscyamine's effects on gastrointestinal motility and gastric emptying, absorption of other oral medications may be decreased during concurrent use with this combination medication. Methylene blue inhibits a range of CYP isozymes in vitro, including 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5. This interaction c…
Frequently Asked Questions
What is Uretron D/S used for?
Uretron D/S contains Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate. It is a tablet taken oral. Consult your doctor for specific uses.
Is Uretron D/S a controlled substance?
Uretron D/S is not classified as a controlled substance by the DEA.
What is the generic name for Uretron D/S?
The generic name for Uretron D/S is Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate. There are no other listed brand versions of Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine Sulfate.
What is the NDC code for Uretron D/S .12 mg/1?
The NDC (National Drug Code) for Uretron D/S .12 mg/1 is 12539-144, listed by DORAL PHARMAMEDICS INC dba A.G. Marin Pharmaceuticals.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)